Clinical Trials Arena May 31, 2024
The vaccine being trialled utilises mRNA technology and is tailored to the individual’s cancer mutations.
The NHS has commenced a clinical trial offering personalised cancer vaccines being developed by BioNTech and Genentech to patients. The first patient was treated with a bespoke vaccine for bowel cancer at University Hospitals Birmingham NHS Foundation Trust.
This trial is part of NHS England’s Cancer Vaccine Launch Pad initiative.
BioNTech is sponsoring the colorectal cancer vaccine trial.
The company will present preliminary data, highlighting the potential of circulating tumour DNA in the early detection of colorectal cancer.
The vaccine being trialled utilises mRNA technology, similar to that of the Pfizer-BioNTech Covid-19 vaccine and is tailored to the individual’s cancer mutations.
Thousands of patients are...
Today's Sponsors
Today's Sponsor